{"id":976,"date":"2026-10-08T08:01:30","date_gmt":"2026-10-08T08:01:30","guid":{"rendered":"https:\/\/coloderm.com\/blog\/skin-cancer-screening-cpt-codes-and-icd-10-codes-explained\/"},"modified":"2026-10-08T08:01:30","modified_gmt":"2026-10-08T08:01:30","slug":"skin-cancer-screening-cpt-codes-and-icd-10-codes-explained","status":"publish","type":"post","link":"https:\/\/coloderm.com\/blog\/skin-cancer-screening-cpt-codes-and-icd-10-codes-explained\/","title":{"rendered":"Skin Cancer Screening CPT Codes and ICD-10 Codes Explained"},"content":{"rendered":"\n\n\n\n\n

A skin cancer check can be over in fifteen minutes, but the paperwork it generates often lists several five-digit CPT codes and a separate diagnosis code. Those numbers are not random. Each one tells an insurer what happened during the visit, from the exam itself to a biopsy to the lab work that follows.<\/p>\n\n

Knowing what the common codes mean makes it easier to read an explanation of benefits, spot a duplicate charge, and ask informed questions before you owe anything. This guide walks through the codes that appear most often around skin cancer screening, biopsies, pathology, and Mohs surgery, using published coding references<\/a> and payer policy documents as the source.<\/p>\n\n

There Is No Single Skin Cancer Screening CPT Code<\/h2>\n\n

One of the most common assumptions patients make is that a skin cancer screening has its own dedicated code. Based on the coding references reviewed for this article, that is not the case. No standalone screening code for skin cancer appears in those sources.<\/p>\n\n

Instead, a screening visit is generally reported with an evaluation and management (E\/M) code, the same family of codes used for any office visit. A published review of skin cancer screening encounters between January 2011 and December 2015 lists 99203 among the codes tied to those visits, alongside 11100 and 88305. That mix tells a story: an office visit code for the examination, a biopsy code when a lesion is sampled, and a pathology code when the sample is analyzed in a lab.<\/p>\n\n

Because the exam itself is what drives the billing, the final cost of a screening depends on what the dermatologist finds and what happens next. A visual check that ends with “everything looks fine, see you next year” produces a very different claim than a visit that includes a biopsy.<\/p>\n\n

The CPT Codes Most Often Linked to Skin Cancer Care<\/h2>\n\n

The codes below come up repeatedly in dermatology coding references and payer policy documents. They cover the visit, the procedure, and the lab work.<\/p>\n\n

Evaluation and Management Visits (99203 and Similar Codes)<\/h3>\n\n

The office visit code is the foundation of most skin cancer related claims. It reflects the history your dermatologist takes, the examination performed, and the medical decision making involved. In the published screening encounter review mentioned above, 99203 was the E\/M code listed. The specific E\/M code on your claim depends on the complexity of the visit, so two patients seen on the same day may not carry the same code.<\/p>\n\n

Skin Biopsy Codes (11102 Through 11107)<\/h3>\n\n

When a lesion looks suspicious, the dermatologist may remove a sample for testing. Coding references group 11102 through 11107 as skin biopsy codes, covering techniques such as punch and shave biopsies. The code reported depends on the technique used and the number of lesions sampled. The screening encounter review also lists 11100, another biopsy code, which shows that more than one code from the biopsy family can appear on a skin cancer related claim.<\/p>\n\n

Pathology Codes (88305)<\/h3>\n\n

Once tissue is removed, it travels to a lab for microscopic examination. That step is reported separately, and 88305 is the pathology code listed in the same screening encounter review. This is why patients sometimes receive two bills for one small procedure: one from the dermatology practice for removing the tissue, and one from the lab for reading it. The pathology report also produces the diagnosis that gets attached to the claim.<\/p>\n\n

Mohs Micrographic Surgery (17305)<\/h3>\n\n

For certain skin cancers, particularly on the face where preserving healthy tissue matters, Mohs micrographic surgery<\/a> may be recommended. CPT code 17305 describes a two-stage Mohs micrographic surgery procedure for removing skin cancer that involves up to five tissue specimens. Coding references for 17305 also address whether a modifier is needed, which matters because modifiers can change how a payer processes the claim. If you are scheduled for Mohs, ask the billing office how the stages and specimens will be reported.<\/p>\n\n

Whole Body Photography (96904)<\/h3>\n\n

Some patients, especially those with many moles or a personal history of melanoma, have their skin documented with a set of baseline photographs. Coding guidance notes that CPT code 96904 may be submitted to describe whole body photography. These images give the dermatologist a reference point for spotting changes at the next visit, and they are usually reported in addition to the examination itself.<\/p>\n\n

Optical and Digital Lesion Analysis<\/h3>\n\n

Dermatoscopy, also called dermoscopy or epiluminescence microscopy, lets a clinician examine diagnostic features in pigmented skin lesions directly. A second category, multispectral digital skin lesion analysis (MSDSLA), is a noninvasive approach to diagnosing skin lesions and is described in policy language as analysis of clinically atypical cutaneous pigmented lesions for detection of melanomas and high risk melanocytic atypia. Both approaches are covered inconsistently, which is why payer policy language matters so much for these services.<\/p>\n\n\n

\n \n \n \n \n \n \n \n
Code<\/th>\n What it describes<\/th>\n <\/tr>\n
99203<\/td>\n Office visit code listed in a published review of skin cancer screening encounters<\/td>\n <\/tr>\n
11102 to 11107<\/td>\n Skin biopsy codes, including punch and shave techniques<\/td>\n <\/tr>\n
11100<\/td>\n Biopsy code also listed in the same screening encounter review<\/td>\n <\/tr>\n
88305<\/td>\n Pathology code reported when a specimen is examined in the lab<\/td>\n <\/tr>\n
17305<\/td>\n Two-stage Mohs micrographic surgery involving up to five tissue specimens<\/td>\n <\/tr>\n
96904<\/td>\n Whole body photography<\/td>\n <\/tr>\n<\/table><\/figure>\n\n\n
\"skin
Photo by Gustavo Fring<\/a> on Pexels<\/a><\/figcaption><\/figure>\n\n

ICD-10 Codes Describe the Diagnosis, Not the Service<\/h2>\n\n

CPT codes answer “what was done.” ICD-10 codes answer “why.” A claim normally carries at least one diagnosis code that supports the service being billed, and for skin cancer that code describes the specific type and location of the lesion.<\/p>\n\n

Published listings for non-melanoma skin cancer include \u200bC44.319 for basal cell carcinoma of skin of other parts of face, and C44.320 for squamous cell carcinoma of skin of unspecified parts of face. The squamous cell series continues with C44.321. The pattern is worth noticing: these codes carry both a cancer type and a body site, because payers want to know exactly which cancer is being treated and where.<\/p>\n\n

If you have ever wondered why your dermatologist measures and describes a lesion so carefully, this is part of the reason. The documentation has to support the code that gets submitted.<\/p>\n\n

Why One Visit Can Produce Several Codes<\/h2>\n\n

A single appointment can legitimately generate an office visit code, a biopsy code, and a pathology code, because three distinct services were provided. That is not double billing. What would be a problem is the same service reported twice without reason, or a procedure code reported without a supporting diagnosis.<\/p>\n\n

This is also where modifiers come in. The reference material for CPT 17305 includes a section specifically on modifiers, which reflects how often payers need extra information to understand the relationship between two procedures performed on the same day. If your claim is denied or reduced, a missing modifier is one of the first things a billing office checks.<\/p>\n\n

\"medical
Photo by Pixabay<\/a> on Pexels<\/a><\/figcaption><\/figure>\n\n

Coverage Policy Changes, So Verify Before You Assume<\/h2>\n\n

Payer policies do not stay still. The policy covering optical diagnostic devices used to evaluate skin lesions suspected of malignancy carries an effective date of June 1, 2009, with a last update of November 6, 2018. A separate policy on multispectral digital skin lesion analysis carries an effective date of January 1, 2021, and lists committee approval dates stretching back years.<\/p>\n\n

The code set changes too. When CPT updates were introduced for 2021, they added code 71271 for low dose CT thorax for lung cancer screening and 76145 for medical physics dose evaluation for radiation exposure. New codes appear regularly, and coverage decisions follow.<\/p>\n\n

The practical takeaway is simple. Ask your insurer whether the specific service is covered<\/a> under your plan, in writing if possible, and ask your dermatology office which codes they expect to submit. Neither the code list nor the coverage rules in this article should be treated as your final answer, because your plan’s current policy is the document that decides what you owe.<\/p>\n\n

Questions Worth Asking Before Your Appointment<\/h2>\n\n